Results 1 to 10 of about 923 (130)

Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study [PDF]

Advanced Science
Azvudine is recommended as a priority treatment for patients with Coronavirus Disease 2019 (COVID‐19) during Omicron wave in China, but its efficacy and safety in elderly patients is unknown.
Ranran Sun, Haiyu Wang, Junyi Sun, Mengzhao Yang, Shixi Zhang, Xinjun Hu, Bo Yu, Zhan Song, Na Han, Hong Luo, Ming Cheng, Guangming Li, Guotao Li, Yiqiang Yuan, Lili Liang, Yanyang Zhang, Donghua Zhang, Silin Li, Quancheng Kan, Hongxia Liang, Zhigang Ren   +20 more
doaj   +6 more sources

Advances in the effectiveness and safety of azvudine treatment: a comprehensive review [PDF]

Frontiers in Pharmacology
The global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed for human immunodeficiency virus (HIV), has gained attention for its ...
Jiayi Li, Jiayi Li, Bo Zhu, Bo Zhu, Jian Lu, Zheyi Dong, Ping Li, Wenge Li, Chunfu Zheng, Junbiao Chang, Shunlai Shang, Shunlai Shang   +11 more
doaj   +7 more sources

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19 [PDF]

BMC Infectious Diseases
Purpose To compare the effectiveness and safety of two antiviral drugs, azvudine and nirmatrelvir/ritonavir, in treating hospitalized patients with COVID-19.
Jin Yang, Jiao Min, Ling Ding, Rong Liu, Ya Yang, Jian-feng Zhang, Wei Lei   +6 more
doaj   +7 more sources

Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study [PDF]

Scientific Reports
Azvudine is recommended for patients with coronavirus disease 19 (COVID-19); however, its optimum therapeutic time window and its impact on mortality of patients are unclear.
Luo Wang, Yaqi Wang, Yan Xu, Junping Fan, Siqi Pan, Huaiya Xie, Ting Zhang, Ruxuan Chen, Xiaoyan Liu, Chuan Shi, Qing Zhou, Yuequan Shi, Chongsheng Cheng, Lu Dai, Haoran Zhang, Aohua Wu, Xueqi Liu, Hong Zhang, Jinglan Wang, Bin Du, Jihai Liu, Huadong Zhu, Xiaojun Ma, Jing Huang, Xinlun Tian, Mengzhao Wang, Shuyang Zhang   +26 more
doaj   +6 more sources

Real-World Evaluation Study of Azvudine for the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Conclusions: Azvudine significantly reduced the hospitalization time and the time to nucleic acid conversion to negative in COVID-19 patients and significantly lowered all-cause mortality (Grading of Recommendations Assessment, Development, and ...
Abiden Kapar, Huling Li, Qian He, Dandan Lin, Dandan Tang, Kai Peng, Yida Wang, Kai Wang   +7 more
doaj   +6 more sources

Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis [PDF]

Virology Journal
Background Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate the safety of azvudine and its effectiveness in reducing mortality. Methods PubMed, Embase, Web of
Yaqi Wang, Huaiya Xie, Luo Wang, Junping Fan, Ying Zhang, Siqi Pan, Wangji Zhou, Qiaoling Chen, Xueqi Liu, Aohua Wu, Hong Zhang, Jinglan Wang, Xinlun Tian   +12 more
doaj   +7 more sources

A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes [PDF]

Frontiers in Endocrinology
IntroductionDuring the Omicron infection wave, diabetic patients are susceptible to COVID-19, which is linked to a poor prognosis. However, research on the real-world effectiveness and safety of Azvudine, a common medication for COVID-19, is insufficient
Yongjian Zhou, Zecheng Yang, Shixi Zhang, Donghua Zhang, Hong Luo, Di Zhu, Guangming Li, Mengzhao Yang, Xiaobo Hu, Guowu Qian, Guotao Li, Ling Wang, Silin Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +5 more sources

Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19).
Jing Zhang, Fang Wang, Ying Xie, Qianyu Li, Zhenzhen Zhu, Yuan Dong   +5 more
doaj   +5 more sources

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]

BMJ Open
Objectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang, Zhigang Ren, Xiaoli Jin, Hong Luo, Donghua Zhang, Ming Cheng, Fuwei Wang, Bohan Jia, Guotao Li, Mengzhao Yang, Guangming Li, Shixi Zhang, Guowu Qian, Silin Li, Hongxia Liang   +14 more
doaj   +4 more sources

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes [PDF]

iScience
Summary: Azvudine and nirmatrelvir-ritonavir are prioritized treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in hospitalized patients with COVID-19 and pre-existing diabetes remains unknown.
Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren   +18 more
doaj   +4 more sources